letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...1415161718192021222324...100101»
  • ||||||||||  Phase classification, Enrollment change:  SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) -  Aug 8, 2023   
    P1,  N=25, Not yet recruiting, 
    Trial completion date: Aug 2023 --> Dec 2023 Phase classification: P2 --> P1 | N=131 --> 25
  • ||||||||||  letrozole / Generic mfg.
    Journal:  CangFu Daotan decoction improves polycystic ovarian syndrome by downregulating FOXK1. (Pubmed Central) -  Aug 6, 2023   
    High-fat diet and letrozole were combined to establish PCOS rat models...Interestingly, treatment with CFD reversed all the effects of FOXK1 overexpression in GCs. This study demonstrated that CFD exerted a protective role in PCOS by inhibiting FOXK1, which provided a research basis for the application of CFD in PCOS, and suggested that FOXK1 is a novel therapeutic target in PCOS treatment.
  • ||||||||||  Metastatic Breast Cancer Presenting as Colon Polyp Decade After Remission (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3529;    
    The patient has been on continuous hormonal therapy with Letrozole 2.5 mg daily and has remained clinically disease-free...(B) Diffuse uptake of GATA3 stain is seen within the atypical cells. (C) Diffuse uptake of ER stain is seen within the atypical cells.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Kisqali (ribociclib) / Novartis
    Disseminated Invasive Lobular Carcinoma Metastasis of the Gastrointestinal Tract: An Oncologic Anomaly (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_2162;    
    An adjuvant therapy of Letrozole + Ribociclib was immediately initiated, and patient was discharged to follow up with oncology...Due to presence of skeletal metastasis, Denosumab was added for suppression of skeletal metastasis and secondary fracture prevention...Figure: Endoscopy and Colonoscopy evaluation of lesions: Endoscopy demonstrated Schatzki ring at the gastroesophageal junction (a), scattered inflammation and erythema in stomach (b), and severe intrinsic stenosis of pylorus (c). Colonoscopy demonstrating intrinsic stenosis of proximal rectum (d), and nodular erythematous mucosa of the transverse colon (e) and cecum (f).
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Metastatic Breast Cancer Masquerading as Colonic Mass (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_689;    
    The analysis of cases as the one above can lay the groundwork in forming cohort of patients to study the polarity of metastatic patterns. Figure: (a)diffuse wall thickening of descending colon (b) coronal view, notable for gastric abutment of transverse colon (c) tissue sample demonstrating linear single-file cells, ER +, PR-, resembling histologically primary breast lesion
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Preclinical, Journal:  Ziziphus mauritiana Leaves Normalize Hormonal Profile and Total Cholesterol in Polycystic Ovarian Syndrome Rats. (Pubmed Central) -  Jul 29, 2023   
    The present study showed an improvement in the inflammatory microenvironment of the ovarian tissue in the PCOS rat model. This research concluded that the leaves of Ziziphus mauritiana have potential efficacy in the treatment of PCOS by normalizing abnormal hormones and total cholesterol levels, which could be due to the presence of quercetin in the leaves.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Invasive disease (Bilbao Auditorium - NCC) -  Jul 27, 2023 - Abstract #ESMO2023ESMO_1283;    
    P3
    EBC. Table: LBA23 Tx, n 3-y iDFS rate, % HR (95% CI) Menopausal status Premenopausal women & men Postmenopausal women RIB + NSAI, 1126 NSAI alone, 1132 RIB + NSAI, 1423 NSAI alone, 1420 91 89 90 86 0.72 (0.53-0.98) 0.78 (0.61-1.00) Anatomical stage II III RIB + NSAI, 1011 NSAI alone, 1034 RIB + NSAI, 1528 NSAI alone, 1512 94 91 87 84 0.76 (0.53-1.10) 0.74 (0.59-0.93) Nodal status N0 N1-N3 RIB + NSAI, 285 NSAI alone, 328 RIB + NSAI, 2261 NSAI alone, 2219 94 89 90 87 0.63 (0.34-1.17) 0.77 (0.63-0.94) Age 20% RIB + NSAI, 1199 NSAI alone, 1236 RIB + NSAI, 920 NSAI alone, 938 92 90 89 84 0.80 (0.59-1.08) 0.75 (0.56-1.00)
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Comparison of Three Ovulation Induction Therapies for Patients With Polycystic Ovary Syndrome and Infertility. (Pubmed Central) -  Jul 26, 2023   
    In this retrospective study, we compared the success rates of 90 patients who underwent intrauterine insemination (IUI), who were randomly assigned to one of three treatment groups: letrozole (LE) + urinary gonadotropin (HMG), clomiphene (CC) + HMG, or HMG alone...This protocol increased ovulation, boosted fertility, and enhanced endometrial receptivity with no increase in adverse reactions. Therefore, it may be a useful clinical approach for inducing ovulation and treating infertility in patients with PCOS.
  • ||||||||||  letrozole / Generic mfg., fulvestrant / Generic mfg.
    Review, Journal:  The Application of 18F-FES PET in Clinical Cancer Care: A Systematic Review. (Pubmed Central) -  Jul 24, 2023   
    [18F]fluoroestradiol PET is not only a convenient and accurate diagnostic imaging tool for detecting ER-expressing lesions in patients with breast and ovarian cancer but also among patients with uterine cancer. [18F]fluoroestradiol PET is a noninvasive predictive and monitoring tool for treatment response and prognosis.
  • ||||||||||  lerociclib (G1T38) / Walvax, Pepper Bio
    Enrollment closed, Metastases:  A Study of Lerociclib in Participants With Advanced Breast Cancer (clinicaltrials.gov) -  Jul 21, 2023   
    P2,  N=100, Active, not recruiting, 
    Trial completion date: Jul 2027 --> Sep 2026 Recruiting --> Active, not recruiting
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  The Letrozole Administration During Luteal Phase (clinicaltrials.gov) -  Jul 20, 2023   
    P3,  N=50, Not yet recruiting, 
    Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jun 2023 Trial completion date: Mar 2017 --> Dec 2024 | Trial primary completion date: Dec 2016 --> Mar 2024
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Jul 20, 2023   
    P2,  N=19, Active, not recruiting, 
    Trial completion date: Mar 2017 --> Dec 2024 | Trial primary completion date: Dec 2016 --> Mar 2024 Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: May 2023 --> Oct 2023
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Preclinical, Journal:  In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment. (Pubmed Central) -  Jul 18, 2023   
    Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: May 2023 --> Oct 2023 This is the first in vitro study that highlights the potential benefit of G as an adjuvant therapy with Exe, emphasizing, however, that soy derivatives widely used in the diet or applied as auxiliary medicines may increase the risk of adverse interactions with nonsteroidal AIs used in therapy.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS. (Pubmed Central) -  Jul 18, 2023   
    Exosomes were used to treat androgen-producing H293R cells and injected in a mouse model through intraovarian and intravenous injection into a letrozole (LTZ)-induced PCOS mouse model...Our study suggests that MSC-derived exosomes can be promising biopharmaceutics for treating PCOS conditions as a novel therapeutic option. Despite the fact that we need more validation in human patients, we may evaluate this novel treatment option for PCOS with the following clinical trials.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents. (Pubmed Central) -  Jul 17, 2023   
    Molecular docking and molecular dynamics calculations on the interaction of 6 or letrozole with the aromatase binding site revealed that the ferrocene moiety increases the van der Waals and hydrophobic interactions, thus resulting in an increase in binding affinity. Furthermore, the iron atom of the ferrocene fragment can form a metal-acceptor interaction with a propionate fragment, and this results in a stronger coupling with the heme group-a possibility that is consistent with the strong aromatase inhibition of 6.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change:  Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (clinicaltrials.gov) -  Jul 17, 2023   
    P1,  N=24, Completed, 
    Furthermore, the iron atom of the ferrocene fragment can form a metal-acceptor interaction with a propionate fragment, and this results in a stronger coupling with the heme group-a possibility that is consistent with the strong aromatase inhibition of 6. Recruiting --> Completed | N=60 --> 24
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Follicular steroidogenesis in random start protocols for oocyte cryopreservation. (Pubmed Central) -  Jul 13, 2023   
    However, our study found contradictory effects of KD on the gut microbiome in PCOS, which need further research. The endocrine microenvironment surrounding oocytes is not markedly influenced by the phase of the menstrual cycle at the
  • ||||||||||  letrozole / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon (clinicaltrials.gov) -  Jul 12, 2023   
    P1,  N=16, Active, not recruiting, 
    The endocrine microenvironment surrounding oocytes is not markedly influenced by the phase of the menstrual cycle at the Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Aug 2023